Type 1 diabetes: Continuous glucose monitoring

A statement from an ATTD consensus group has streamlined previously agreed continuous glucose monitoring metrics and set out time in range targets.

Most hypoglycemia outcomes measured by real-time continuous glucose monitoring can be used to predict future severe hypoglycemia in people with type 1 diabetes, with similar levels of accuracy, study findings indicate.

Exposure to hypoglycemia deceases significantly with increasing levels of insulin suspension automation in people with type 1 diabetes, real‐world study data show.

People with type 1 diabetes have high-priority concerns that go beyond glucose control, including complex and mentally taxing treatment and weight gain, report researchers.

Even with newer devices, continuous glucose monitoring underestimates the fall in glucose levels during exercise, with the drop lagging significantly behind that measured by self-monitoring of blood glucose, research shows.

People with type 1 diabetes at high hypoglycemia risk using insulin pumps have fewer hypoglycemic events if the pump is linked to a continuous glucose monitor and has a suspend-before-low feature, SMILE study data show.

The frequency at which people with type 1 diabetes experience hypoglycemia decreases during the first 30 days after they switch to a continuous glucose monitor that incorporates a predictive low-glucose alert, research shows.

Baseline data from the WISDM trial show that older adults with type 1 diabetes who have impaired awareness of hypoglycemia symptoms can spend over half an hour per day with extremely low blood glucose levels.

Using continuous glucose monitoring for all women with type 1 diabetes during pregnancy could save the UK National Health Service over 9 million pounds per year, report the CONCEPTT investigators.

Giving children continuous glucose monitoring from the point of diabetes diagnosis gives their caregivers greater confidence to manage hypoglycemia and reduces their diabetes-related distress, shows a randomized trial.

Continuous glucose monitoring has a less impressive effect on patient-reported outcomes than on glycemic control among patients with type 1 diabetes, reveal the HypoDE investigators.

Home use of day and night hybrid closed-loop insulin delivery using the Cambridge model predictive control algorithm is feasible in children aged 1–7 years with type 1 diabetes, researchers report.

A prespecified analysis of the CONCEPTT trial shows that pregnant women with type 1 diabetes who were using pumps at baseline did not achieve as good glycemic control as those using multiple daily injections.

The Tandem Basal-IQ predictive low-glucose suspend insulin delivery system significantly reduces the proportion of time adults and children spend in hypoglycemia during 24-hour usage, show findings from the randomized crossover PROLOG trial.

Researchers have reported good accuracy, durability, and acceptability of the Eversense continuous glucose monitoring system in a group of primarily pediatric patients.

Prepubertal children with type 1 diabetes have greater glycemic variability than those who are pubertal or postpubertal, researchers have reported at the ADA’s 78th Scientific Sessions.

Just 1 week of continuous glucose monitoring can uncover hidden problems and lead to treatment changes and improved glucose control in patients with type 1 diabetes, say the DIACCOR study investigators.

Analysis of the DIAMOND study shows that continuous glucose monitoring in patients with type 1 diabetes could be considered cost-effective, although this depends on the value for money threshold used.

The HypoDE investigators have reported that use of continuous glucose monitoring results in large reductions in hypoglycemia among high-risk patients managing their type 1 diabetes with multiple daily injections.

Further findings from the pilot I-HART randomized trial suggest that switching from flash to continuous glucose monitoring reduces the time patients with type 1 diabetes spend in hypoglycemia